Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.89
WST's Cash-to-Debt is ranked lower than
60% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. WST: 0.89 )
Ranked among companies with meaningful Cash-to-Debt only.
WST' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.29 Max: 0.92
Current: 0.89
0.17
0.92
Equity-to-Asset 0.65
WST's Equity-to-Asset is ranked higher than
63% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. WST: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
WST' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.45 Max: 0.65
Current: 0.65
0.35
0.65
Interest Coverage 24.30
WST's Interest Coverage is ranked lower than
57% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. WST: 24.30 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.4  Med: 7.99 Max: 24.3
Current: 24.3
5.4
24.3
Piotroski F-Score: 8
Altman Z-Score: 8.36
Beneish M-Score: -2.52
WACC vs ROIC
10.16%
12.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.04
WST's Operating Margin % is ranked higher than
70% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. WST: 13.04 )
Ranked among companies with meaningful Operating Margin % only.
WST' s Operating Margin % Range Over the Past 10 Years
Min: 8.21  Med: 10.07 Max: 13.04
Current: 13.04
8.21
13.04
Net Margin % 9.51
WST's Net Margin % is ranked higher than
71% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. WST: 9.51 )
Ranked among companies with meaningful Net Margin % only.
WST' s Net Margin % Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 9.52
Current: 9.51
5.91
9.52
ROE % 13.12
WST's ROE % is ranked higher than
75% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. WST: 13.12 )
Ranked among companies with meaningful ROE % only.
WST' s ROE % Range Over the Past 10 Years
Min: 9.65  Med: 13.52 Max: 17.69
Current: 13.12
9.65
17.69
ROA % 8.42
WST's ROA % is ranked higher than
78% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. WST: 8.42 )
Ranked among companies with meaningful ROA % only.
WST' s ROA % Range Over the Past 10 Years
Min: 5.09  Med: 6.34 Max: 8.42
Current: 8.42
5.09
8.42
ROC (Joel Greenblatt) % 20.82
WST's ROC (Joel Greenblatt) % is ranked higher than
66% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.86 vs. WST: 20.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WST' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.75  Med: 17.48 Max: 21.35
Current: 20.82
12.75
21.35
3-Year Revenue Growth Rate 1.60
WST's 3-Year Revenue Growth Rate is ranked lower than
60% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. WST: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WST' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 6.6 Max: 17.8
Current: 1.6
-2.9
17.8
3-Year EBITDA Growth Rate 3.30
WST's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. WST: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WST' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.3  Med: 7 Max: 16.8
Current: 3.3
-9.3
16.8
3-Year EPS without NRI Growth Rate 6.80
WST's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. WST: 6.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WST' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -15  Med: 7.1 Max: 57.4
Current: 6.8
-15
57.4
GuruFocus has detected 4 Warning Signs with West Pharmaceutical Services Inc $WST.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WST's 10-Y Financials

Financials (Next Earnings Date: 2017-05-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

WST Guru Trades in Q1 2016

Columbia Wanger 317,164 sh (New)
Paul Tudor Jones 4,400 sh (New)
Jim Simons 514,200 sh (-0.06%)
Ken Fisher 1,228,363 sh (-0.95%)
Ron Baron 2,310,171 sh (-2.44%)
RS Investment Management 1,586,533 sh (-17.44%)
Ruane Cunniff 533,650 sh (-46.20%)
» More
Q2 2016

WST Guru Trades in Q2 2016

Paul Tudor Jones 14,000 sh (+218.18%)
Columbia Wanger 924,372 sh (+191.45%)
Ken Fisher 1,235,850 sh (+0.61%)
Ron Baron 2,274,371 sh (-1.55%)
Ruane Cunniff 443,019 sh (-16.98%)
RS Investment Management 1,253,102 sh (-21.02%)
Jim Simons 45,900 sh (-91.07%)
» More
Q3 2016

WST Guru Trades in Q3 2016

Jim Simons Sold Out
Ron Baron 2,258,479 sh (-0.70%)
Ken Fisher 1,222,462 sh (-1.08%)
Ruane Cunniff 424,467 sh (-4.19%)
Paul Tudor Jones 12,557 sh (-10.31%)
Columbia Wanger 781,437 sh (-15.46%)
» More
Q4 2016

WST Guru Trades in Q4 2016

Chuck Royce 23,000 sh (New)
Paul Tudor Jones Sold Out
Ken Fisher 1,170,631 sh (-4.24%)
Ron Baron 2,138,775 sh (-5.30%)
Ruane Cunniff 373,781 sh (-11.94%)
Columbia Wanger 606,983 sh (-22.32%)
» More
» Details

Insider Trades

Latest Guru Trades with WST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:BIOL, NAS:BLFS, NAS:BMRA, NYSE:BAX, NYSE:BDX » details
Traded in other countries:WPS.Germany,
West Pharmaceutical Services Inc is a manufacturer of components & systems for injectable drug delivery, plastic packaging, delivery system components. Its products include stoppers and seals for vials, prefillable syringe components and systems.

West Pharmaceutical Services Inc was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923. The Company is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. Majority of its business is conducted in healthcare markets. Its reportable segments are Proprietary Products and Contract-Manufactured Products. Proprietary Products offers proprietary packaging, containment, and drug delivery products. The packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability, while also supporting operational efficiency. Proprietary Products also offers syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications. The Company competes with several companies across its product lines. Competition is based mainly on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost control programs across their entire operations. The design, development, manufacturing, marketing, and labeling of certain of the Company's products and its customer's products that incorporate its products are subject to regulation by governmental authorities in the United States, Europe, and other countries, including the FDA and the European Medicines Agency.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services - Jan 30, 2017

Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services Guru stock highlight
Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries. Read more...
Baron Funds Comments on West Pharmaceutical Services Guru stock highlight
West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years. Read more...

Ratios

vs
industry
vs
history
PE Ratio 42.42
WST's PE Ratio is ranked lower than
69% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.58 vs. WST: 42.42 )
Ranked among companies with meaningful PE Ratio only.
WST' s PE Ratio Range Over the Past 10 Years
Min: 12.28  Med: 22.83 Max: 64.85
Current: 42.42
12.28
64.85
Forward PE Ratio 32.26
WST's Forward PE Ratio is ranked lower than
73% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.77 vs. WST: 32.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.42
WST's PE Ratio without NRI is ranked lower than
69% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. WST: 42.42 )
Ranked among companies with meaningful PE Ratio without NRI only.
WST' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.28  Med: 22.95 Max: 64.85
Current: 42.42
12.28
64.85
Price-to-Owner-Earnings 115.76
WST's Price-to-Owner-Earnings is ranked lower than
85% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. WST: 115.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WST' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.16  Med: 39.27 Max: 173.32
Current: 115.76
19.16
173.32
PB Ratio 5.31
WST's PB Ratio is ranked lower than
72% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.39 vs. WST: 5.31 )
Ranked among companies with meaningful PB Ratio only.
WST' s PB Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2.92 Max: 5.67
Current: 5.31
1.74
5.67
PS Ratio 4.01
WST's PS Ratio is ranked lower than
61% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. WST: 4.01 )
Ranked among companies with meaningful PS Ratio only.
WST' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.57 Max: 4.29
Current: 4.01
1.02
4.29
Price-to-Free-Cash-Flow 124.28
WST's Price-to-Free-Cash-Flow is ranked lower than
91% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.63 vs. WST: 124.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WST' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.49  Med: 46.29 Max: 381.09
Current: 124.28
18.49
381.09
Price-to-Operating-Cash-Flow 27.67
WST's Price-to-Operating-Cash-Flow is ranked lower than
74% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.91 vs. WST: 27.67 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WST' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 12.01 Max: 29.59
Current: 27.67
7.55
29.59
EV-to-EBIT 30.15
WST's EV-to-EBIT is ranked lower than
73% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.63 vs. WST: 30.15 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 18.8 Max: 53.3
Current: 30.15
11.2
53.3
EV-to-EBITDA 20.68
WST's EV-to-EBITDA is ranked lower than
68% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.65 vs. WST: 20.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 12 Max: 27.6
Current: 20.68
7.6
27.6
PEG Ratio 6.06
WST's PEG Ratio is ranked lower than
80% of the 55 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.82 vs. WST: 6.06 )
Ranked among companies with meaningful PEG Ratio only.
WST' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.07 Max: 50.27
Current: 6.06
1.01
50.27
Shiller PE Ratio 58.59
WST's Shiller PE Ratio is ranked lower than
70% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.61 vs. WST: 58.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
WST' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.08  Med: 33.22 Max: 62.78
Current: 58.59
19.08
62.78
Current Ratio 2.66
WST's Current Ratio is ranked higher than
55% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.37 vs. WST: 2.66 )
Ranked among companies with meaningful Current Ratio only.
WST' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.14 Max: 2.94
Current: 2.66
1.5
2.94
Quick Ratio 1.84
WST's Quick Ratio is ranked higher than
58% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. WST: 1.84 )
Ranked among companies with meaningful Quick Ratio only.
WST' s Quick Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.57 Max: 2.28
Current: 1.84
1.09
2.28
Days Inventory 70.49
WST's Days Inventory is ranked higher than
85% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. WST: 70.49 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 52.45  Med: 64.65 Max: 70.1
Current: 70.49
52.45
70.1
Days Sales Outstanding 48.49
WST's Days Sales Outstanding is ranked higher than
76% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.14 vs. WST: 48.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 47.63 Max: 50.44
Current: 48.49
41.76
50.44
Days Payable 44.18
WST's Days Payable is ranked lower than
57% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.97 vs. WST: 44.18 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 39.47 Max: 46.32
Current: 44.18
29.33
46.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.62
WST's Dividend Yield % is ranked lower than
79% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.16 vs. WST: 0.62 )
Ranked among companies with meaningful Dividend Yield % only.
WST' s Dividend Yield % Range Over the Past 10 Years
Min: 0.57  Med: 1.23 Max: 2.01
Current: 0.62
0.57
2.01
Dividend Payout Ratio 0.26
WST's Dividend Payout Ratio is ranked higher than
74% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. WST: 0.26 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WST' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.23  Med: 0.27 Max: 0.35
Current: 0.26
0.23
0.35
3-Year Dividend Growth Rate 8.40
WST's 3-Year Dividend Growth Rate is ranked lower than
57% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.10 vs. WST: 8.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WST' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 5.2  Med: 6.5 Max: 8.4
Current: 8.4
5.2
8.4
Forward Dividend Yield % 0.64
WST's Forward Dividend Yield % is ranked lower than
84% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. WST: 0.64 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.89
WST's 5-Year Yield-on-Cost % is ranked lower than
74% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.53 vs. WST: 0.89 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WST' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.81  Med: 1.74 Max: 2.85
Current: 0.89
0.81
2.85
3-Year Average Share Buyback Ratio -1.40
WST's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. WST: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: -1.3 Max: 4.8
Current: -1.4
-4
4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 139.71
WST's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 106 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.27 vs. WST: 139.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WST' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 146.26  Med: 1076.8 Max: 2007.33
Current: 139.71
146.26
2007.33
Price-to-Tangible-Book 5.98
WST's Price-to-Tangible-Book is ranked lower than
60% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. WST: 5.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.07  Med: 3.17 Max: 6.87
Current: 5.98
2.07
6.87
Price-to-Intrinsic-Value-Projected-FCF 4.07
WST's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. WST: 4.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WST' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.27  Med: 2.24 Max: 4.26
Current: 4.07
1.27
4.26
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.67
WST's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
90% of the 21 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.07 vs. WST: 3.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 2.56
WST's Price-to-Median-PS-Value is ranked lower than
93% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. WST: 2.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WST' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 0.86 Max: 2.68
Current: 2.56
0.54
2.68
Price-to-Peter-Lynch-Fair-Value 7.74
WST's Price-to-Peter-Lynch-Fair-Value is ranked lower than
98% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. WST: 7.74 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WST' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.98  Med: 1.73 Max: 13.06
Current: 7.74
0.98
13.06
Price-to-Graham-Number 3.36
WST's Price-to-Graham-Number is ranked lower than
65% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. WST: 3.36 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WST' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.04  Med: 1.72 Max: 3.55
Current: 3.36
1.04
3.55
Earnings Yield (Greenblatt) % 3.32
WST's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. WST: 3.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WST' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.3 Max: 8.9
Current: 3.32
1.9
8.9
Forward Rate of Return (Yacktman) % 6.54
WST's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. WST: 6.54 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WST' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.7  Med: 10 Max: 22.2
Current: 6.54
-3.7
22.2

More Statistics

Revenue (TTM) (Mil) $1,509
EPS (TTM) $ 1.91
Beta1.08
Short Percentage of Float2.05%
52-Week Range $64.75 - 88.30
Shares Outstanding (Mil)73.33

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 2.51
EPS without NRI ($) 2.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for WST

Headlines

Articles On GuruFocus.com
Baron Asset Fund Comments on West Pharmaceutical Services Jan 30 2017 
Baron Asset Fund 4th Quarter Shareholder Letter Jan 30 2017 
Baron Funds Comments on West Pharmaceutical Services Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Weekly CEO Buys Highlight: WST, PHII, CLMS, CSBK, AMRC May 26 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Is Cooper Companies' Upward Trend Likely to Go On? Mar 25 2014 
Illumina Inc: How Long Can a Miracle Go On? Feb 07 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
The Best Dividends on April 16, 2012 Apr 13 2012 

More From Other Websites
West Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : January 18th, 2017 (record date) :... Mar 16 2017
WEST PHARMACEUTICAL SERVICES INC Financials Mar 03 2017
WEST PHARMACEUTICAL SERVICES INC Files SEC form 10-K, Annual Report Feb 28 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: 2016 By the Numbers : February 21,... Feb 21 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 17 2017
Edited Transcript of WST earnings conference call or presentation 16-Feb-17 2:00pm GMT Feb 16 2017
West Pharmaceutical Services Inc Earnings Call scheduled for 9:00 am ET today Feb 16 2017
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 16 2017
West Pharmaceutical misses Street 4Q forecasts Feb 16 2017
West Pharmaceutical misses Street 4Q forecasts Feb 16 2017
Q4 2016 West Pharmaceutical Services Inc Earnings Release - Before Market Open Feb 16 2017
West Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend Feb 16 2017
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX Feb 15 2017
West to Host Fourth-Quarter and Full-Year 2016 Conference Call Feb 02 2017
West Introduces LyoSeal® Instant Sealing Solution and NovaGuard® SA Pro Safety System at... Feb 01 2017
Baron Asset Fund Comments on West Pharmaceutical Services Jan 30 2017
Baron Asset Fund 4th Quarter Shareholder Letter Jan 30 2017
West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : January 25, 2017 Jan 25 2017
West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bearish Manner : WST-US :... Jan 24 2017
ETFs with exposure to West Pharmaceutical Services, Inc. : January 20, 2017 Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)